Navigation Links
Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
Date:6/28/2010

e are two major types of diabetes: type 1 and type 2. Type 1, previously known as juvenile diabetes or insulin-dependent diabetes, is a disorder involving the body's immune system. In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result of the decrease in endogenous (natural) insulin production, patients must monitor their glucose levels frequently and administer insulin regularly to control their blood glucose levels.

About Otelixizumab

Otelixizumab is a targeted T cell immunomodulator being developed for the treatment of type 1 diabetes and other autoimmune diseases. Otelixizumab targets CD3, a T lymphocyte receptor involved in normal cell signaling. Otelixizumab has not yet been approved for marketing. Data suggest that the antibody may work in patients with type 1 diabetes who have residual beta cells by blocking the function of effector T cells that mistakenly attack and destroy insulin-producing beta cells, while stimulating regulatory T cells that are understood to protect against effector T cell damage, thus preserving the beta cells' ability to make insulin.

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses.  The company also has three pre-clinical candidates, TRX518, TRX585 and TRX385, that enhance immune responses and as such are being evaluated fo
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
7. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
8. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  Health Catalyst, ... analytics, today launched Health Catalyst Academy ... help health systems build the internal capacity ... operational efficiency. Health Catalyst ... Catalyst,s comprehensive suite of outcomes-improvement solutions and ...
(Date:5/26/2015)... May 26, 2015  PAREXEL International Corporation (NASDAQ: ... at the Goldman Sachs Healthcare Conference in Palos Verdes, ... Executive Officer, will be making a presentation on PAREXEL ... Tuesday, June 9, 2015. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
(Date:5/26/2015)...  Halyard Health, Inc. (NYSE: HYH ) today announced ... will present at the 2015 Morgan Stanley Leveraged Finance Conference ... a.m., CDT on Thursday, June 4. A webcast ... section of the Halyard Health website at https://halyardhealth.investorroom.com/ ... About Halyard Health: Halyard Health (NYSE: HYH ...
Breaking Medicine Technology:Introducing Health Catalyst Academy: An Innovative Approach for Accelerating Outcomes Improvement 2Introducing Health Catalyst Academy: An Innovative Approach for Accelerating Outcomes Improvement 3Introducing Health Catalyst Academy: An Innovative Approach for Accelerating Outcomes Improvement 4PAREXEL International To Present At Goldman Sachs Healthcare Conference 2
... announces that a new market research report is ... Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) ... Drug delivery is evolving at a rapid rate ... Advanced drug delivery deals with developing solutions for ...
... Reportlinker.com announces that a new market research ... France Pharmaceutical Market Overview – Austerity measures ... http://www.reportlinker.com/p0360215/France-Pharmaceutical-Market-Overview-–--Austerity-measures-will-impact-pharmaceutical-market-growth.html Introduction ... France was valued at $38.8bn in sales in ...
Cached Medicine Technology:Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 2Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 3Reportlinker Adds France Pharmaceutical Market Overview - Austerity measures will impact pharmaceutical market growth 2
(Date:5/27/2015)... The Case Management Society of America has ... Lifetime Achievement Award, to Anne Llewellyn RN-BC, MS, BHSA, ... at the association’s 25th Annual Conference and Expo at ... CMSA Board of Directors awards the Lifetime Achievement Award ... contribution to practice of case management and in support ...
(Date:5/27/2015)... May 27, 2015 Water, ... water filtration products, has announced that its elite ... of the first to pass the new NSF/ANSI ... certification is monumental, proving that the BG-12000 by ... pharmaceuticals, over-the-counter medications, and chemicals used in manufacturing ...
(Date:5/27/2015)... One of America's most cherished actors, James Earl Jones, ... takes a look at the topic of atrial fibrillation. ... heart rhythm. Those who suffer from atrial fibrillation have ... quickly. , This new segment will take a look ... inform viewers about possible signs that commonly indicate the ...
(Date:5/27/2015)... 27, 2015 HomeTown Health, along with ... north Georgia cities on May 13 & 14. In ... physicians to meet with the group of representatives and ... and office staff attended. , Referred to as ... to bring together Health Information Technology and ICD-10 resources ...
(Date:5/26/2015)... In celebration of Parker and Sons forty years of ... HVAC systems with a high Season Energy Efficiency Rating (SEER) ... a SEER rating around 15-16 can be purchased for under ... with a SEER rating, it is essentially what miles per ... amount of energy expended by the actual heating and cooling ...
Breaking Medicine News(10 mins):Health News:CMSA to Present Prestigious Lifetime Achievement Award to Anne Llewellyn RN-BC, MS, BHSA, CCM, CRRN 2Health News:Water, Inc.’s BG-12000 Body Glove Water Filter System Receives NSF/ANSI Standard 401 Certification for Pharmaceutical Emerging Contaminant Reduction 2Health News:Water, Inc.’s BG-12000 Body Glove Water Filter System Receives NSF/ANSI Standard 401 Certification for Pharmaceutical Emerging Contaminant Reduction 3Health News:HomeTown Health Leads Rural Physician Bus Tour; Brings Resources and Education to North Georgia 2Health News:HomeTown Health Leads Rural Physician Bus Tour; Brings Resources and Education to North Georgia 3Health News:Parker and Sons Recounts its Path to Success 2
... Aug. 17 Hypertronics C ... of high performance interconnect solutions for the most demanding applications ... by Biosense Webster, Inc. for its new CARTO((R)) 3 Navigation ... signal reliability and ease of use as a push pull ...
... Trust for America,s Health (TFAH) applauds six of the nation,s ... a central part of health reform. , ... Robert Wood Johnson Foundation, W.K. Kellogg Foundation, and Kaiser Permanente ... focus on community prevention will improve health, save money, reduce ...
... as a group have lower rates of thinking about ... women seem to be particularly at risk for suicidal ... study shows 15.93 percent of U.S.-born Asian-American women have ... 13.5 percent for all Americans. The finding comes ...
... N.J., Aug. 17 Wyeth (NYSE: WYE ) (the ... of all of its outstanding Wyeth Floating Rate Convertible Senior Debentures ... of August 14, 2009, there was $22,664,000 in aggregate principal amount ... will be redeemed by the Company at a cash purchase price ...
... , , , ... WASHINGTON, Aug. 17 With two storms swirling ... people who live in hurricane-prone areas to update their preparedness plans. ... "Just this weekend Tropical Storm Claudette formed very quickly in the ...
... , ST. PAUL, Minn., Aug. ... particle pollution like smoke and smog, as well as other ... airborne contaminants to experience shortness of breath, wheezing and coughing, ... According to AIRNow.gov(2), a government-developed index for reporting daily air ...
Cached Medicine News:Health News:Hypertronics Circular HyperGrip(R) Connectors Selected for Biosense Webster's CARTO(R) 3 Navigation System 2Health News:Trust for America's Health Praises Major Foundations for Supporting Prevention as a Central Part of Health Reform 2Health News:US-born Asian-American women more likely to think about, attempt suicide 2Health News:US-born Asian-American women more likely to think about, attempt suicide 3Health News:Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024 2Health News:Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024 3Health News:Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024 4Health News:Hurricane Season Heats Up 2Health News:Hurricane Season Heats Up 3Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 2Health News:Bad Air Day Alert: Outdoor Air Pollutants at High Level 3
Long handle occluders are approximately 9 inches long....
Manual Lensmeter....
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
Medicine Products: